Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use

Patent metadata

Field	Value
Publication number	US-2016256459-A1
Application number	US-201615152653-A
Country	US
Kind code	A1
Filing date	May 12, 2016
Priority date	Jan 30, 2014
Publication date	Sep 8, 2016
Grant date	—

Abstract

Provided herein are formulations, processes, solid forms and methods of use relating to 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide.

First claim

1 - 20 . (canceled)

21 . A method for treating a condition treatable by inhibition of a kinase pathway, comprising administering to a subject having a condition treatable by inhibition of a kinase pathway an effective amount of a crystal form of Compound 1, or a tautomer thereof:

22 . The method of claim 21 , wherein the crystal form has an X-ray powder diffraction pattern comprising peaks at 10.55, 13.61 and 19.84±0.2° 2θ.

23 . The method of claim 21 , wherein the crystal form has an X-ray powder diffraction pattern comprising peaks at 9.80, 17.29, 20.66 and 21.74±0.2° 2θ.

24 . The method of claim 21 , wherein the crystal form has an X-ray powder diffraction pattern comprising peaks at 9.83, 10.21, 17.26 and 21.86±0.2° 2θ.

25 . The method of claim 21 , wherein the crystal form has an X-ray powder diffraction pattern comprising peaks at 10.37, 13.41, 19.52 and 22.47±0.2° 2θ.

26 . The method of claim 21 , wherein the crystal form has an X-ray powder diffraction pattern comprising peaks at 9.92, 17.29, 20.10 and 21.81±0.2° 2θ.

27 . The method of claim 21 , wherein the crystal form has an X-ray powder diffraction pattern comprising peaks at 18.53, 20.85 and 21.10±0.2° 2θ.

28 . The method of claim 21 , wherein the crystal form has an X-ray powder diffraction pattern comprising peaks at 9.51, 10.34, 17.90 and 21.28±0.2° 2θ.

29 . The method of claim 21 , wherein the crystal form has an X-ray powder diffraction pattern comprising peaks at 9.74, 17.22, 18.04 and 21.76±0.2° 2θ.

30 . The method of claim 21 , wherein the crystal form has an X-ray powder diffraction pattern comprising peaks at 7.94, 16.00 and 18.27±0.2° 2θ.

31 . A method for treating interstitial pulmonary fibrosis, systemic sclerosis, scleroderma, chronic allograft nephropathy, antibody mediated rejection, or lupus, comprising administering to a subject having interstitial pulmonary fibrosis, systemic sclerosis, scleroderma, chronic allograft nephropathy, antibody mediated rejection, or lupus an effective amount of a crystal of comprising Compound 1, or a tautomer thereof:

32 . The method of claim 31 , wherein the crystal form has an X-ray powder diffraction pattern comprising peaks at 10.55, 13.61, 17.20 and 19.84±0.2° 2θ.

33 . The method of claim 31 , wherein the crystal form has an X-ray powder diffraction pattern comprising peaks at 9.80, 17.29, 20.66 and 21.74±0.2° 2θ.

34 . The method of claim 31 , wherein the crystal form has an X-ray powder diffraction pattern comprising peaks at 9.83, 10.21, 17.26 and 21.86±0.2° 2θ.

35 . The method of claim 31 , wherein the crystal form has an X-ray powder diffraction pattern comprising peaks at 10.37, 13.41, 19.52 and 22.47±0.2° 2θ.

36 . The method of claim 31 , wherein the crystal form has an X-ray powder diffraction pattern comprising peaks at 9.92, 17.29, 20.10 and 21.81±0.2° 2θ.

37 . The method of claim 31 , wherein the crystal form has an X-ray powder diffraction pattern comprising peaks at 18.53, 20.85 and 21.10±0.2° 2θ.

38 . The method of claim 31 , wherein the crystal form has an X-ray powder diffraction pattern comprising peaks at 9.51, 10.34, 17.90 and 21.28±0.2° 2θ.

39 . The method of claim 31 , wherein the crystal form has an X-ray powder diffraction pattern comprising peaks at 9.74, 17.22, 18.04 and 21.76±0.2° 2θ.

40 . The method of claim 31 , wherein the crystal form has an X-ray powder diffraction pattern comprising peaks at 7.94, 16.00 and 18.27±0.2° 2θ.

41 . The method of claim 31 , wherein the subject has interstitial pulmonary fibrosis.

42 . A method for treating a liver fibrotic disorder, diabetes, metabolic syndrome leading to a liver fibrotic disorder, or a condition treatable by inhibition of a kinase pathway, comprising administering to a subject having a liver fibrotic disorder, diabetes, metabolic syndrome leading to a liver fibrotic disorder, or a condition treatable by inhibition of a kinase pathway an effective amount a crystal form of Compound 1, or a tautomer thereof:

43 . The method of claim 42 , wherein the crystal form has an X-ray powder diffraction pattern comprising peaks at 10.55, 13.61, 17.20 and 19.84±0.2° 2θ.

44 . The method of claim 42 , wherein the crystal form has an X-ray powder diffraction pattern comprising peaks at 9.80, 17.29, 20.66 and 21.74±0.2° 2θ.

45 . The method of claim 42 , wherein the crystal form has an X-ray powder diffraction pattern comprising peaks at 9.83, 10.21, 17.26 and 21.86±0.2° 2θ.

46 . The method of claim 42 , wherein the crystal form has an X-ray powder diffraction pattern comprising peaks at 10.37, 13.41, 19.52 and 22.47±0.2° 2θ.

47 . The method of claim 42 , wherein the crystal form has an X-ray powder diffraction pattern comprising peaks at 9.92, 17.29, 20.10 and 21.81±0.2° 2θ.

48 . The method of claim 42 , wherein the crystal form has an X-ray powder diffraction pattern comprising peaks at 18.53, 20.85 and 21.10±0.2° 2θ.

49 . The method of claim 42 , wherein the crystal form has an X-ray powder diffraction pattern comprising peaks at 9.51, 10.34, 17.90 and 21.28±0.2° 2θ.

50 . The method of claim 42 , wherein the crystal form has an X-ray powder diffraction pattern comprising peaks at 9.74, 17.22, 18.04 and 21.76±0.2° 2θ.

51 . The method of claim 42 , wherein the crystal form has an X-ray powder diffraction pattern comprising peaks at 7.94, 16.00 and 18.27±0.2° 2θ.

Assignees

• Signal Pharm Llc

Inventors

• Man Hon-Wah
• Xu Jean
• Beauchamps Marie Georges
• Kothare Mohit Atul
• Zou Nanfei
• Li Ying
• Huang Lianfeng
• Zou Daozhong

Classifications

• C07D239/42

  One nitrogen atom (nitro radicals C07D239/30) · CPC title

• C07D239/48 Primary

  Two nitrogen atoms · CPC title

• A61K31/505 Primary

  Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim · CPC title

• C07B2200/13

  Crystalline forms, e.g. polymorphs · CPC title

• C07D239/28 Primary

  with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms · CPC title